贝伐珠单抗一线治疗转移性结直肠癌的疗效:系统综述与荟萃分析
该系统综述与荟萃分析检索EMBASE、MEDLINE和Cochrane图书馆(2018年4月),纳入7项随机研究,评估贝伐珠单抗联合一线化疗治疗转移性结直肠癌的附加疗效。总体分析中,贝伐珠单抗联合化疗较单纯化疗显著改善无进展生存期(HR 0.71,p<0.00001)和总生存期(HR 0.85,p=0.0008)。但仅分析当前常用方案时,联合贝伐珠单抗显著延长无进展生存期(HR 0.79,p<0.0001)而未显著延长总生存期(HR 0.92,p=0.18);联合氟尿嘧啶单药时,无进展生存期(HR 0.57,p<0.00001)和总生存期(HR 0.83,p=0.03)均显著延长。
要点
- 总体分析中,贝伐珠单抗联合化疗较单纯化疗显著改善无进展生存期(HR 0.71,p<0.00001)和总生存期(HR 0.85,p=0.0008)。
- 仅分析当前常用化疗方案(输注5-FU联合伊立替康或奥沙利铂)时,联合贝伐珠单抗显著延长无进展生存期(HR 0.79,p<0.0001),但总生存期未达统计学显著(HR 0.92,p=0.18)。
- 联合氟尿嘧啶单药时,贝伐珠单抗显著延长无进展生存期(HR 0.57,p<0.00001)和总生存期(HR 0.83,p=0.03)。
核心结论
- 贝伐珠单抗对生存的效应在各纳入方案中并不一致;仅分析当前常用方案时,仅在贝伐珠单抗联合氟尿嘧啶单药时观察到对无进展生存期和总生存期的显著效应。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、MEDLINE和Cochrane图书馆(2018年4月),纳入7项随机研究。
主要发现
- 总体分析中,贝伐珠单抗联合化疗较单纯化疗显著改善无进展生存期(HR 0.71,p<0.00001)和总生存期(HR 0.85,p=0.0008)。
- 仅分析当前常用化疗方案(排除5-FU推注方案,仅含输注5-FU联合伊立替康或奥沙利铂)时,联合贝伐珠单抗显著延长无进展生存期(HR 0.79,p<0.0001),但总生存期未达统计学显著(HR 0.92,p=0.18)。
- 联合氟尿嘧啶单药时,贝伐珠单抗显著延长无进展生存期(HR 0.57,p<0.00001)和总生存期(HR 0.83,p=0.03)。
关键数值与推荐
- 总体效应:无进展生存期HR 0.71(p<0.00001),总生存期HR 0.85(p=0.0008),均 favour 贝伐珠单抗联合化疗。
- 当前常用方案(输注5-FU联合伊立替康或奥沙利铂):无进展生存期HR 0.79(p<0.0001),总生存期HR 0.92(p=0.18)。
- 氟尿嘧啶单药联合贝伐珠单抗:无进展生存期HR 0.57(p<0.00001),总生存期HR 0.83(p=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This systematic review and meta-analysis aims to evaluate the additive effect of bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer (mCRC). METHODS: We searched EMBASE, MEDLINE, the Cochrane Library in April 2018. When possible, data were pooled to estimate summary effects. The present analysis evaluated treatment related efficacy based on progression-free survival (PFS) and overall survival (OS). The analysis was performed to define the overall effect and the effect observed in currently used chemotherapy regimens. RESULTS: Seven randomised studies were included. In the analysis of the overall effect, PFS (hazard ratio [HR] 0.71, p < 0.00001) and OS (HR 0.85, p = 0.0008) clearly favoured bevacizumab plus chemotherapy versus chemotherapy alone. When the analysis was focused on currently used chemotherapy excluding 5-FU bolus regimens and including only infusional 5-FU plus irinotecan or oxaliplatin, the addition of bevacizumab prolonged PFS (HR 0.79, p < 0.0001) but not OS (HR 0.92, p = 0.18). However, addition of bevacizumab to fluoropyrimidine monotherapy lead to a significant prolongation of PFS (HR 0.57, p < 0.00001) and OS (HR 0.83, p = 0.03). CONCLUSION: The present meta-analysis demonstrates that the effect of bevacizumab on survival is not consistent throughout the included regimens. Considering only presently used regimens, a significant effect on PFS and OS was only observed when bevacizumab was added to fluoropyrimidine monotherapy.
引用
- Baraniskin A, Buchberger B, Pox C, et al. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Eur J Cancer. 2018. PMID: 30476731. doi:10.1016/j.ejca.2018.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。